Drug Policy Myths vs Facts: Why Punishment Hasn't Worked

Portugal decriminalized all personal-use drugs in 2001. In the two decades since, drug use rates among Portuguese adults have remained at or below the European average. Youth drug use declined. Overdose deaths dropped from 80 per million in 2001 to 3 per million by 2017 — one of the lowest rates in Europe. Decriminalization did not create a wave of new users.

The confusion lies in equating legal consequences with deterrence. Research consistently shows that criminal penalties have almost no measurable effect on whether people decide to try drugs. What does affect drug use rates is availability of treatment, public health education, and social conditions. When Portugal redirected its enforcement budget toward treatment and harm reduction, drug-related HIV infections fell by 95% and drug-related deaths dropped by over 80%.

Oregon's 2020 decriminalization experiment has been cited as a counterexample, but it rolled back penalties without investing in the treatment infrastructure that made Portugal's model work. Decriminalization without treatment access isn't a policy — it's an absence of policy. The evidence from Portugal, the Czech Republic, and the Netherlands consistently shows that decriminalization paired with robust treatment reduces both use and harm.

The American Medical Association, the American Society of Addiction Medicine, the National Institute on Drug Abuse, and every major medical organization in the world classifies addiction as a chronic brain disorder — not a character defect. Repeated drug exposure physically alters the brain's reward circuitry, decision-making centers, and stress response systems. These are measurable, observable changes on brain scans.

Addiction has a heritability rate of 40-60%, comparable to type 2 diabetes and heart disease. No one calls diabetes a moral failing. The "moral failing" framework persists because it serves a political purpose: if addiction is a choice, then the solution is punishment rather than expensive treatment infrastructure. This framing has shaped US drug policy for a century and has failed to reduce addiction rates.

The moral model also ignores the role of the pharmaceutical industry. The opioid epidemic was created by Purdue Pharma and other companies that knowingly marketed addictive painkillers as safe. Over 80% of heroin users started with prescription opioids prescribed by a doctor. Calling their addiction a "moral failing" absolves the corporations and regulators who created the crisis.

The United States has spent over $1 trillion on drug enforcement since 1971. During that time, drug use rates have not declined. Overdose deaths have increased from roughly 6,000 per year in 1980 to over 110,000 per year in 2023. Incarceration for drug offenses has increased by over 1,000%. By every measure, the enforcement-first approach has produced the opposite of its stated goals.

Arresting drug users does not treat addiction — it interrupts lives, destroys employment, separates families, and creates criminal records that make recovery harder. People released from prison for drug offenses face higher overdose risk (the first two weeks after release are the deadliest), lower employment prospects, and restricted access to housing, education, and public benefits. The arrest-incarceration cycle actively worsens outcomes.

Countries that shifted from enforcement to treatment saw dramatic improvements. Switzerland's heroin-assisted treatment program reduced crime among participants by 60%, reduced homelessness by 80%, and reduced illegal drug use by 82%. The US could achieve similar results, but it would require acknowledging that fifty years of enforcement-first policy has been a trillion-dollar failure.